Science in Boston covered Tonix Pharmaceuticals licensing agreement with UMass Chan for TNX-4800, highlighting the strength of the collaboration and the program’s potential as a breakthrough in seasonal Lyme disease prevention. Read more: tinyurl.com/muytc8dk

Tonix CEO Seth Lederman launches his new Substack — a forum for science, policy & innovation in chronic pain. His first post: Suffering We Can Stop: The cruel choice between pain and addiction 🔗 bit.ly/48k3iYL #ChronicPain #OpioidCrisis #TNXP #Biotech

PharmaVoice recently highlighted Tonmya™, the first newly approved fibromyalgia therapy in over 15 years. This milestone reflects the growing importance of advancing non-opioid treatment options for patients living with chronic conditions like fibromyalgia and underscores

Proactive Investors reported on Tonix Pharmaceuticals advancement of TNX-102 SL for depression following a positive FDA meeting, highlighting the strengthened development path for this important program. Read more here: tinyurl.com/bdvr8zb7

Tonix Pharmaceuticals applauds the 2025 Nobel Prize winners in Physiology or Medicine for their discovery and characterization of regulatory T cells (Tregs). Tonix’s investigational TNX-1500 (anti-CD40L) preserves Tregs in animal models of organ transplantation, an effect we believe may

“When waiting hurts.” Millions live with post-infectious chronic illnesses like #Fibromyalgia, #LongLyme, and #LongCOVID. Tonix CEO Dr. Seth Lederman calls for urgent collaboration to accelerate research and relief. Read more: bit.ly/4qd2lb5 #TonixPharma #IACI

In a new op-ed, Tonix CEO Dr. Seth Lederman shares why now is the moment to accelerate innovation against today’s toughest health challenges from chronic pain and infection-associated illnesses to emerging pathogens. Read the op-ed: bit.ly/47k11uo #AIinHealthcare

Tonix Pharmaceuticals announced the first patient dosed in the investigator-initiated FOCUS pilot study of its investigational intranasal potentiated oxytocin (TNX-1900/TNX-2900) in Arginine-Vasopressin Deficiency (AVP-D), conducted by Massachusetts General Hospital. The study will

Tonix Pharmaceuticals presented data on TNX-102 SL (cyclobenzaprine HCL sublingual tablets) at the 2025 ACR Convergence, highlighting clinically meaningful pain reduction and symptom improvement in the Phase 3 RESILIENT study. TNX-102 SL significantly reduced fibromyalgia pain versus

Progress happens faster when patients and science move together. In a new op-ed, Tonix CEO Dr. Seth Lederman shares how patient experiences inspired innovation in chronic pain, leading to the first new fibromyalgia therapy in adults in over 15 years. 🔗bit.ly/47oLppC

Tonix Pharmaceuticals will present at BIO-Europe 2025, taking place November 3–5 in Vienna, Austria. Seth Lederman, M.D., Chief Executive Officer, will present on Tuesday, November 4, highlighting Tonix’s strategy, pipeline, and upcoming milestones.

Gender bias still affects how patients are heard and treated. In his new Substack essay, Tonix CEO @SethLedermanMD shares a perspective on closing the care gap through better data, awareness, and empathy. bit.ly/4omALXA #HealthEquity #PatientCare #TonixPharma

Tonix Pharmaceuticals announced a collaboration with Massachusetts General Hospital to advance an investigator-initiated Phase 2 study of TNX-1500, a dimeric Fc-modified anti-CD40L antibody, in kidney transplant recipients. The study is expected to begin in the first half of 2026 and will

We’re heading to the Stifel 2025 Healthcare Conference this week. Seth Lederman, M.D., CEO of Tonix Pharmaceuticals, will present on Thursday, November 13 at 10:00 AM ET. Join the live webcast here: tinyurl.com/4x4nttwd

Today, Tonix Pharmaceuticals announced its Q3 2025 earnings, highlighting $190 million in cash as of the end of Q3, with a cash runway into Q1 2027, and strong momentum heading into the end of the year as the company prepares to launch Tonmya, the first FDA-approved treatment for

It’s today! Tune in at 10:00 AM ET as Seth Lederman, M.D., CEO of Tonix Pharmaceuticals, presents at the Stifel 2025 Healthcare Conference. Catch the live webcast here: bit.ly/4p1RY8G

Today we launched the first therapy approved in the US for fibromyalgia in 15 years. We are proud to provide patients a new therapeutic option. Read more here: bit.ly/48fcayl

We’re proud to report the FDA has cleared our IND for TNX-102 SL in Major Depressive Disorder. Clinical trials in MDD are scheduled to start in 2026. This milestone reflects our commitment to studying TNX-102 SL in new indications where there is significant unmet medical need.